Tourmaline Bio Debt to Equity

As of the most recent data, TRML shows a debt-to-equity ratio of 0.0. That is below the Healthcare sector average of 0.3. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.3. Tourmaline Bio is at 0.0, which is lower that average. That is roughly 99.8% below the sector mean. Use the comparison chart on this page to see how TRML stacks up against individual peers as well.

Investors watch TRML's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Tourmaline Bio's latest reading is 0.0. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Tourmaline Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.0) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.3, while TRML is at 0.0. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.